Kanga Articles

Welcome Guest


Web Design, SEO & Internet Marketing - Kanga Articles » Health-and-fitness » Ferric Carboxymaltose Injection for Iron Deficiency Anemia

Ferric Carboxymaltose Injection for Iron Deficiency Anemia

View PDF | Print View
by: Guest
Total views: 687
Word Count: 714

Ferric carboxymaltose injection with the brand name Injectafer is a parental iron replacement product which was approved by USFDA in July 2013, for the treatment of iron deficiency anemia in adults who have showed intolerance to oral iron or have had a poor response to oral Injectafer is also indicated for iron deficiency anemia in adult patients with non-dialysis dependent chronic kidney disease was developed by Luitpold pharmaceutical Inc, a Daiichi Sankyo Group Company, headquartered in Shirley, New The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging is a mineral that is very much needed by the body to produce red blood When the body does not get enough iron, it cannot produce the required number of red blood cells and this condition is called iron deficiency Iron-deficiency can occur due to insufficient dietary intake and absorption of iron, and/or loss of iron as a result ofinternal bleeding which can originate from a range of sources such as the intestinal, uterine or urinary Thus theoccurrence of iron deficiency anemia can be the result of our body not making enough red blood cells or due to bleeding that causes loss of red blood cells more quickly than they can be Iron deficiency anemia affect women more often than deficiency anemia ischaracterized by the signs of pallor and/or symptoms of fatigue, light-headedness, and weakness that are Pallor is a condition of the skin becoming pale as a result of reduced amounts of oxyhaemoglobin in the skin or mucous with active ingredient ferric carboxymaltose is a dark brown, sterile, aqueous, isotonic colloidal solution for intravenous The dosage of Injectafer is expressed as milligram of elemental recommended dose of Injectafer is 15 mg/kg with a total cumulative dose not exceeding 1500mg of elemental Injectafer can be given in two separate doses for atleast 7 Each mL of Injectafer contains 50 mg of elemental Injectafer is available in 15 mL single-use vials containing 750mg of elemental Injectafer can be administered intravenously either as an undiluted slow intravenous push or by Injectafer treatment may be repeated if iron deficiency anemia FDA approval of Injectafer was based on the safety and efficacy that was evaluated in two randomized, open label, comparator controlled clinical trials (Trial1 and included iron deficiency anemia patients who were intolerant to oral iron or have had unsatisfactory response to oral iron for a 14 day They were then randomised into two groups and given twice daily dose of 750 mg Injectafer for group 1 and thrice daily of 325 mg oral/IV ironfor group 2, for another 14 On day 35, the mean increase of haemoglobin from baseline was found to be g/dL and g/dL for Injectafer and oral/IV iron Trial2 was on iron deficiency anemia patients with non-dialysis dependent chronic kidney 2 compared thrice daily of 750 mg Injectafer to five daily doses of 200 mg Day 56,the mean increase of haemoglobin from baseline was found to be g/dL and g/dL for Injectafer and venofer Venofer is an iron sucrose injection to treat iron deficiency anemia patients with chronic kidney disease in adults and paediatric children older than 2 Venofer is administered as a total cumulative dose of 1000 mg as a 200 mg slow IV injection undiluted over 2 to 5 minutes on 5 different major side effects reported for Injectafer are hypersensitivity reactions, injection site discoloration, hypertension, nausea, vomiting, dizziness, head ache, and Some of the adverse reactions reported are abdominal pain, diarrhoea, rash, paraesthesia, and Transient decreases in blood phosphorus levels have also been one should pay utmost caution during administration of IV Injectafer to avoid any extravasation of the drug since the brown discoloration at the extravasation site may be long lasting; extravasation is the leakage of intravenous drugs from the vein into the surrounding If extravasation occurs, one should discontinue the drug administration at that is a new option for adults who have intolerance to oral iron or have had a poor response to oral It is also proved to be effective in patients with Non-Dialysis Dependent Chronic Kidney Clinical trials have also confirmed that Injectafer showed a gradual increase in ferritin levels in the blood with no renal elimination of

About the Author

Rating: Not yet rated


No comments posted.

Add Comment

You do not have permission to comment. If you log in, you may be able to comment.